These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 21512758)

  • 1. Monthly administration of a novel PTH-collagen binding domain fusion protein is anabolic in mice.
    Ponnapakkam T; Katikaneni R; Miller E; Ponnapakkam A; Hirofumi S; Miyata S; Suva LJ; Sakon J; Matsushita O; Gensure RC
    Calcif Tissue Int; 2011 Jun; 88(6):511-20. PubMed ID: 21512758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single injection of the anabolic bone agent, parathyroid hormone-collagen binding domain (PTH-CBD), results in sustained increases in bone mineral density for up to 12 months in normal female mice.
    Ponnapakkam T; Katikaneni R; Suda H; Miyata S; Matsushita O; Sakon J; Gensure RC
    Calcif Tissue Int; 2012 Sep; 91(3):196-203. PubMed ID: 22806683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infrequent delivery of a long-acting PTH-Fc fusion protein has potent anabolic effects on cortical and cancellous bone.
    Kostenuik PJ; Ferrari S; Pierroz D; Bouxsein M; Morony S; Warmington KS; Adamu S; Geng Z; Grisanti M; Shalhoub V; Martin S; Biddlecome G; Shimamoto G; Boone T; Shen V; Lacey D
    J Bone Miner Res; 2007 Oct; 22(10):1534-47. PubMed ID: 17576164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis.
    Joseph F; Ahmad AM; Ul-Haq M; Durham BH; Whittingham P; Fraser WD; Vora JP
    J Bone Miner Res; 2008 May; 23(5):721-9. PubMed ID: 18052753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normal epidermal growth factor receptor signaling is dispensable for bone anabolic effects of parathyroid hormone.
    Schneider MR; Dahlhoff M; Andrukhova O; Grill J; Glösmann M; Schüler C; Weber K; Wolf E; Erben RG
    Bone; 2012 Jan; 50(1):237-44. PubMed ID: 22056328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anabolic actions of PTH (1-34): use of a novel tissue engineering model to investigate temporal effects on bone.
    Pettway GJ; Schneider A; Koh AJ; Widjaja E; Morris MD; Meganck JA; Goldstein SA; McCauley LK
    Bone; 2005 Jun; 36(6):959-70. PubMed ID: 15878317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893.
    Stewart AF; Cain RL; Burr DB; Jacob D; Turner CH; Hock JM
    J Bone Miner Res; 2000 Aug; 15(8):1517-25. PubMed ID: 10934650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unmasking the osteoinductive effects of a G-protein-coupled receptor (GPCR) kinase (GRK) inhibitor by treatment with PTH(1-34).
    Wang L; Quarles LD; Spurney RF
    J Bone Miner Res; 2004 Oct; 19(10):1661-70. PubMed ID: 15355561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice.
    Yamane H; Sakai A; Mori T; Tanaka S; Moridera K; Nakamura T
    Bone; 2009 Jun; 44(6):1055-62. PubMed ID: 19303837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice.
    Samadfam R; Xia Q; Goltzman D
    J Bone Miner Res; 2007 Jan; 22(1):55-63. PubMed ID: 17014384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating osteoporosis by targeting parathyroid hormone to bone.
    Ponnapakkam T; Katikaneni R; Sakon J; Stratford R; Gensure RC
    Drug Discov Today; 2014 Mar; 19(3):204-8. PubMed ID: 23932952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ZT-031, a cyclized analog of parathyroid hormone(1-31) for the potential treatment of osteoporosis.
    Nemeth EF
    IDrugs; 2008 Nov; 11(11):827-40. PubMed ID: 18988128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accretion of bone mass and strength with parathyroid hormone prior to the onset of estrogen deficiency can provide temporary beneficial effects in skeletally mature rats.
    Shen V; Birchman R; Liang XG; Wu DD; Dempster DW; Lindsay R
    J Bone Miner Res; 1998 May; 13(5):883-90. PubMed ID: 9610753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined treatment with a beta-blocker and intermittent PTH improves bone mass and microarchitecture in ovariectomized mice.
    Pierroz DD; Bouxsein ML; Rizzoli R; Ferrari SL
    Bone; 2006 Aug; 39(2):260-7. PubMed ID: 16531131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skeletal unloading alleviates the anabolic action of intermittent PTH(1-34) in mouse tibia in association with inhibition of PTH-induced increase in c-fos mRNA in bone marrow cells.
    Tanaka S; Sakai A; Tanaka M; Otomo H; Okimoto N; Sakata T; Nakamura T
    J Bone Miner Res; 2004 Nov; 19(11):1813-20. PubMed ID: 15476581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skeletal effects of parathyroid hormone infusion in ovariectomized rats with or without estrogen repletion.
    Shen V; Birchman R; Wu DD; Lindsay R
    J Bone Miner Res; 2000 Apr; 15(4):740-6. PubMed ID: 10780865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of hPTHrP (1-36) as an anabolic therapeutic agent for osteoporosis].
    Takeuchi Y
    Clin Calcium; 2011 Jan; 21(1):28-32. PubMed ID: 21187591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermittent PTH(1-34) does not increase union rates in open rat femoral fractures and exhibits attenuated anabolic effects compared to closed fractures.
    Tägil M; McDonald MM; Morse A; Peacock L; Mikulec K; Amanat N; Godfrey C; Little DG
    Bone; 2010 Mar; 46(3):852-9. PubMed ID: 19922821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1.
    Bodine PV; Seestaller-Wehr L; Kharode YP; Bex FJ; Komm BS
    J Cell Physiol; 2007 Feb; 210(2):352-7. PubMed ID: 17044082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance of increased bone mass after recombinant human parathyroid hormone (1-84) with sequential zoledronate treatment in ovariectomized rats.
    Rhee Y; Won YY; Baek MH; Lim SK
    J Bone Miner Res; 2004 Jun; 19(6):931-7. PubMed ID: 15125792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.